Comparative safety and effectiveness of tumor necrosis factor a antagonists and vedolizumab in elderly IBD patients: a multicentre study

Adar T1, Faleck D2, Sasidharan S3, Cushing K1, Borren NZ1, Nalagatla N1, Ungaro R2, Sy W2, Owen SC4, Patel A3, Cohen BL2, Ananthakrishnan AN1. Aliment Pharmacol Ther. 2019 Feb 17. doi: 10.1111/apt.15177. [Epub ahead of print]


Author information

1 Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts.

2 Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York City, New York.

3 Division of Hospital Medicine, Massachusetts General Hospital, Boston, Massachusetts.

4 Division of Gastroenterology, Brooke Army Medical Center, Fort Sam Houston, Texas.


BACKGROUND: The older patient group with inflammatory bowel diseases (IBD) is particularly vulnerable to consequences of disease and therapy-related side effects but little is known about the best treatment options in this population.

AIM: To compare safety and efficacy of tumor necrosis factor α antagonist (anti-TNF) or vedolizumab (VDZ) in patients with IBD >60 years of age.

METHODS: This retrospective study included patients with Crohn's disease (CD) or ulcerative colitis (UC) initiating anti-TNF or VDZ therapy ≥60 years of age at three study sites. We examined occurrence of infection or malignancy within 1 year after therapy as our primary outcome. Our efficacy outcomes included clinical remission at 3, 6 and 12 months. Multivariable logistic regression models adjusting for relevant confounders estimated odds ratios (OR) and 95% confidence intervals.

RESULTS: The study included 131 anti-TNF and 103 VDZ initiated patients (age range 60-88 years). Approximately half had CD. At 1 year, there were no significant differences in safety profile between the two therapeutic classes. Infections were observed in 20% of anti-TNF-treated and 17% of VDZ-treated patients (P = 0.54). Pneumonia was the most common infection in both groups. While more anti-TNF-treated CD patients were in remission at 3 months compared to VDZ (OR 2.82, 95% CI 1.18-6.76), this difference was not maintained at 6 and 12 months suggesting similar efficacy of both classes.

CONCLUSIONS: Both anti-TNF and VDZ therapy were similarly effective and safe in elderly IBD patients.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.